Top

International Orthopaedics

Published in:

01-05-2012 | Original Paper

The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing

Authors: Kambiz Sarahrudi, Georg Kaiser, Anita Thomas, Mark Michel, Harald Wolf, Mehdi Mousavi, Seyedhossein Aharinejad

Published in: International Orthopaedics | Issue 5/2012

Abstract

Purpose

Anticoagulant therapy with low molecular weight heparins (LMWH) and mechanical compression is considered the gold standard for the prevention of thrombosis. However, evidence exists that LMWHs impair bone metabolism. The aim of this study was therefore to analyse alterations in the expression of M-CSF, VEGF and TGF-ß1 after treatment with enoxaparin in patients with long bone fracture to investigate the effect of LMWH on human fracture healing.

Methods

A total of 81 patients with long bone fractures were included in the study and divided into two groups. One group comprised patients who received enoxaparin and the other group, patients who did not receive enoxaparin postoperatively. Growth factor levels were analysed in patients’ serum and different groups were retrospectively compared.

Results

M-CSF serum concentrations were found to be significantly higher only at 48 weeks after surgery in enoxaparin. Mean overall VEGF serum concentration was higher in patients with enoxaparin. TGF-β1 serum concentrations were higher at 48 weeks after surgery in patients with enoxaparin.

Conclusion

This is the first comparative systemic measurement of M-CSF, VEGF and TGF-ß1 serum levels in patients with and without enoxaparin after long bone fracture. Significant differences of the expression of the growth factors after enoxaparin therapy were only observed at week 48 after surgery for M-CSF and TGF-ß1.

Hach W (2002) Die Geschichte der Venoesen Thrombose. Phlebologie 31:56–62

Shefras J, Farquharson RG (1996) Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 65:171–174PubMedCrossRef

Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P (1990) Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rat. Thromb Haemost 63:505–509PubMed

Sarahrudi K, Mousavi M, Thomas A et al (2010) Elevated levels of macrophage colony-stimulating factor (M-CSF) in human fracture healing. J Orthop Res 28(5):671–676PubMed

Dodds RA, Catterall A, Bitensky L, Chayen J (1984) Effects on fracture healing of an antagonist of the vitamin k cycle. Calcif Tissue Int 36(2):233–238PubMedCrossRef

Kock HJ, Werther S, Uhlenkott H, Taeger G (2002) Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model. Unfallchirurg 105(9):791–796PubMedCrossRef

Allen HL, Wase A, Bear WT (1980) Indomethacin and aspirin: effect of nonsteroidal antiinflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand 51(4):595–600PubMed

Street JT, McGrath M, O’Regan K et al (2000) Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res 381:278–289PubMedCrossRef

Hak DJ, Stewart RL, Hazelwood SJ (2006) Effect of low molecular weight heparin on fracture healing in a stabilized rat femur fracture model. J Orthop Res 24(4):645–652PubMedCrossRef

10.

Matziolis G, Perka C, Disch A, Zippel H (2003) Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73(4):370–379PubMedCrossRef

11.

Osip S, Butcher M, Young E et al (2004) Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Thromb Haemost 92:803–810PubMed

12.

Handschin AE, Wanner GA, Trentz OA (2004) Heparin effect on osteoblast-like cells in vitro. J Cell Biochem 93(1):1PubMedCrossRef

13.

Handschin AE, Trentz OA, Hoerstrup SP et al (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (arixtra) on human osteoblasts in vitro. Br J Surg 92(2):177–183PubMedCrossRef

14.

Folwarczna J, Janiec W, Sliwinski L (2004) Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 92(5):940–946PubMed

15.

Nishiyama M, Itoh F, Ujiie A (1997) Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol 74(1):59–68PubMedCrossRef

16.

Hausser HJ, Brenner RE (2004) Low doses and high doses of heparin have different effects on osteoblast-like saos-2 cells in vitro. J Cell Biochem 91(5):1062–1073PubMedCrossRef

17.

Shaughnessy SG, Hirsh J, Bhandari M et al (1999) A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 93(4):1231–1236PubMed

18.

Norrby K (2006) Low-molecular-weight heparins and angiogenesis. APMIS 114:79–102PubMedCrossRef

19.

Marchetti M, Vignoli A, Russo L et al (2008) Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121(5):637–645PubMedCrossRef

20.

Castelli R, Fernando P, Tarsiab P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9:205–213PubMedCrossRef

21.

Norrby K (2000) 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 81:191–198PubMedCrossRef

22.

Gerber H, Vu T, Ryan A et al (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5(6):623–628PubMedCrossRef

23.

Pufe T, Wildemann B, Petersen W et al (2002) Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res 309(3):387–392PubMedCrossRef

24.

Sarahrudi K, Thomas A, Braunsteiner et al (2009) VEGF serum concentrations in patients with long bone fractures: a comparison between impaired and normal fracture healing. J Orthop Res 27(10):1293–1297PubMedCrossRef

25.

Sarahrudi K, Thomas A, Mousavi M et al (2011) Elevated transforming growth factor-beta 1 (TGF-β1) levels in human fracture healing. Injury 42(8):833–837PubMedCrossRef

26.

Sarahrudi K, Thomas A, Heinz T et al (2011) Growth factor release in extra- and intramedullary osteosynthesis following tibial fracture. Injury 42(8):772–777PubMedCrossRef

Title: The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing
Authors: Kambiz Sarahrudi
Georg Kaiser
Anita Thomas
Mark Michel
Harald Wolf
Mehdi Mousavi
Seyedhossein Aharinejad
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: International Orthopaedics / Issue 5/2012
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-011-1392-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Mentoring in complex surgery: minimising the learning curve complications from peri-acetabular osteotomy

The primary stability of angle-stable versus conventional locked intramedullary nails

Retention of a well-fixed acetabular component in the setting of acetabular osteolysis

Management of Vancouver B2 and B3 femoral periprosthetic fractures using a modular cementless stem without allografting

Erratum to: Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery

Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study